Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
NCT01419561Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2011
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of zidovudine, valganciclovir, rituximab, pegylated liposomal doxorubicin in Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICS), sponsored by National Cancer Institute. Started Sep 2011; status: recruiting.
02
Drugs
zidovudinevalganciclovirrituximabpegylated liposomal doxorubicin
03
Conditions
Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICS)
Beyond the preview
Go deeper on NCT01419561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01419561.